Evidence map›Paper›PMID 39417369›Full record

ReviewDeutsches Arzteblatt international2024

Onconephrology: The Significance of Renal Function for the Development, Diagnosis, and Treatment of Cancer.

Susanne Delecluse, Fridtjof Harder, Frieder Keller, Martin Zeier, Stefanie Zschäbitz

Erratum issuedAbstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Pseudo-Worsening of Kidney Function.Deutsches Arzteblatt international · 2025
    Article
  3. In Reply.Deutsches Arzteblatt international · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Susanne DelecluseHeidelberg Kidney Center, Heidelberg, Germany; German Cancer Research Center (DKFZ), Unit D400, Heidelberg, Germany; Institute of Experimental and Clinical Pharmacology, Toxicology, and Pharmacology of Natural Products, Ulm University Medical Center, Ulm, Germany; Department of Internal Medicine VI, Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Fridtjof Harder
Frieder Keller
Martin Zeier
Stefanie Zschäbitz

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundModern treatment strategies have markedly improved the chances of survival for patients with cancer. As the population ages, cancer is becoming more common, as is chronic kidney disease (CKD). CKD increases the risk of cancer; conversely, cancer treatments can cause CKD.

methodsThis review is based on publications retrieved by a selective literature search concerning the epidemiology and comorbidities of cancer and kidney diseases, the renal side effects of new anticancer drugs, and the need to consider renal function in cancer treatment.

resultsThe prevalence of severe CKD in Germany is 2.3%. Persons who have CKD, are on dialysis, or have undergone kidney transplantation are 1.2 to 3.5 times more likely to develop cancer than the general population. For patients who have CKD or are dialysis-dependent, the doses of approximately 67% of anticancer drugs need to be adjusted on the basis of their glomerular filtration rate and the renally excreted fraction of the drug. The optimal efficacy of therapeutic drugs, as well as of those used for diagnostic purposes, and the minimization of side effects, depend critically on adapted dosing and on proper timing of administration before or after dialysis. Modern anticancer drugs can also cause acute kidney damage (incidence with checkpoint inhibitors: 2-16%).

conclusionPatients who have CKD, are on dialysis, or have undergone kidney transplantation make up a considerable fraction of persons being treated for cancer, and they need interdisciplinary treatment.

Indexed as

Antineoplastic AgentsNeoplasmsRenal Insufficiency, ChronicComorbidityGermanyGlomerular Filtration RateHumansKidney TransplantationPrevalenceRenal DialysisRisk FactorsAntineoplastic Agents

Identifiers

PMID39417369
PMCPMC12442801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.